14 completed, 6 active not recruiting, 2 terminated. 12 Phase 1, 10 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 8, Active not recruiting 3, Terminated 1 |
| Phase 2 | 10 | Completed 6, Active not recruiting 3, Terminated 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow Recurrent Pancreatic Carcinoma: new trials by email Literature Review of Recurrent Pancreatic Carcinoma trials Research Report on Recurrent Pancreatic Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 29 | 2021-04-26 | 2026-08-19 |
| Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation Binimetinib, Encorafenib - Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 6 | 2020-11-16 | 2024-05-06 |
| Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Durvalumab, Guadecitabine - Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type | Phase 1 | Active not recruiting | University of Southern California | 55 | 2018-02-07 | 2026-06-01 |
| Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer XL888, Pembrolizumab - Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Completed | Emory University | 47 | 2017-07-07 | 2026-05-22 |
| APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401 - Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm | Phase 1 | Completed | Wake Forest University Health Sciences | 11 | 2017-04-28 | 2024-10-10 |
| FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis - Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 123 | 2016-10-27 | 2026-05-20 |
| Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium - Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Early Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 8 | 2016-10-18 | 2025-04-30 |
| Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer Capecitabine, Fluorouracil, Laboratory Biomarker Analysis - Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Phase 2 | Active not recruiting | University of Nebraska | 46 | 2016-09-16 | 2025-05-25 |
| TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Cyclophosphamide, Laboratory Biomarker Analysis, Pegfilgrastim - Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Terminated | Mayo Clinic | 4 | 2016-02-05 | 2018-09-05 |
| BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer Aldesleukin, Antibody Therapy, Fluorouracil - Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Phase 1 / Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 2 | 2015-12-01 | 2023-05-15 |
| Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer Afatinib Dimaleate, Capecitabine, Laboratory Biomarker Analysis - Advanced Malignant Solid Neoplasm, Bile Duct Carcinoma | Phase 1 | Completed | University of Washington | 41 | 2015-11-05 | 2022-06-07 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-10-22 |
| Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer Gemcitabine, Sorafenib, Vorinostat - Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer | Phase 1 | Completed | Virginia Commonwealth University | 23 | 2015-01-29 | 2022-09-19 |
| Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery Akt Inhibitor MK2206, Dinaciclib, Laboratory Biomarker Analysis - Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2013-01-15 | 2017-08-22 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Pharmacological Study, Romidepsin - Glioma, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 37 | 2012-08-03 | 2025-02-07 |
| Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy Akt Inhibitor MK2206, Fluorouracil, Oxaliplatin - Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 137 | 2012-08-01 | 2016-03-09 |
| Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery Dasatinib, Erlotinib Hydrochloride, Gemcitabine Hydrochloride - Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 19 | 2012-07-30 | 2026-09-09 |
| Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 73 | 2010-12-01 | 2018-03-09 |
| Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Vismodegib - Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 25 | 2010-06-01 | 2017-08-07 |
| Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Gamma-Secretase Inhibitor RO4929097, Cediranib Maleate, Pharmacological Study - Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 1 | Completed | National Cancer Institute (NCI) | 20 | 2010-05-01 | 2014-12-23 |
Showing 20 of 22. Sign in to see all of them.
Pancreatic Neoplasms (22) · Breast Neoplasms (5) · Colorectal Neoplasms (5) · Carcinoma, Renal Cell (4) · Melanoma (4) · Glioma (3) · Neoplasm Metastasis (3) · Ovarian Neoplasms (3) · Prostatic Neoplasms (3) · Brain Neoplasms (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Colonic Neoplasms (2) · Hematologic Neoplasms (2) · Lung Neoplasms (2)
Digestive System Diseases (22) · Digestive System Neoplasms (22) · Endocrine Gland Neoplasms (22) · Endocrine System Diseases (22) · Neoplasms (22) · Neoplasms by Site (22) · Pancreatic Diseases (22) · Gastrointestinal Diseases (7) · Gastrointestinal Neoplasms (7) · Colonic Diseases (6) · Intestinal Diseases (6) · Intestinal Neoplasms (6) · Rectal Diseases (6) · Adenocarcinoma (5) · Breast Diseases (5)
Gemcitabine (6) · Fluorouracil (5) · dehydroftorafur (5) · HhAntag691 (4) · Irinotecan (3) · Leucovorin (3) · Oxaliplatin (3) · Afatinib (2) · Biopsy (2) · Capecitabine (2) · Dasatinib (2) · Erlotinib Hydrochloride (2) · MK 2206 (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2)
National Cancer Institute (NCI) (12) · Academic and Community Cancer Research United (1) · Barbara Ann Karmanos Cancer Institute (1) · Emory University (1) · Mayo Clinic (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of Nebraska (1) · University of Southern California (1) · University of Washington (1) · Virginia Commonwealth University (1) · Wake Forest University Health Sciences (1)
United States (21) · Canada (3) · Guam (1) · Puerto Rico (1)
A P Chen (1) · Andrew E Hendifar (1) · Andrew Poklepovic, MD (1) · Anne Noonan (1) · Anthony El-Khoueiry, MD (1) · Anthony Shields (1) · Charles Erlichman (1) · Chi Lin, MD, PhD (1) · Dana B Cardin (1) · Elena G Chiorean (1) · Elena G. Chiorean (1) · Hedy L Kindler (1) · James Posey, MD (1) · Keith T Flaherty (1) · Maria Diab, MD (1)
PMID 39863139, PMID 25278454, PMID 25931518, PMID 26527777, PMID 26586415, PMID 26719427, PMID 27039845, PMID 27978579, PMID 32463741, PMID 32504550, PMID 32939319, PMID 33048619, PMID 35133871, PMID 35138919, PMID 35362047, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40865033, PMID 41066729
P30CA015083 (3), U01CA132123 (3), U01CA069912 (2), U01CA070095 (2), U10CA180888 (2), UM1CA186644 (2), UM1CA186691 (2), UM1CA186716 (2), N01CM00038 (1), N01CM00070 (1), N01CM00071 (1), N01CM62201 (1), N01CM62204 (1), N01CM62207 (1), N01CM62209 (1)